Global Acute Myeloid Leukemia (AML) Biomarker Testing Market 2023 by Company, Regions, Type and Application, Forecast to 2029

  • receipt Report ID : 345175
  • calendar_today Published On: May, 2023
  • file_copy Pages: 165
  • list Pharmaceuticals and Healthcare
Buy @ $3500

According to our latest study, the global Acute Myeloid Leukemia (AML) Biomarker Testing market size was valued at USD million in 2022 and is forecast to a readjusted size of USD million by 2029 with a CAGR of % during review period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.

This report is a detailed and comprehensive analysis for global Acute Myeloid Leukemia (AML) Biomarker Testing market. Both quantitative and qualitative analyses are presented by company, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2023, are provided.

Key Features:

Global Acute Myeloid Leukemia (AML) Biomarker Testing market size and forecasts, in consumption value ($ Million), 2018-2029

Global Acute Myeloid Leukemia (AML) Biomarker Testing market size and forecasts by region and country, in consumption value ($ Million), 2018-2029

Global Acute Myeloid Leukemia (AML) Biomarker Testing market size and forecasts, by Type and by Application, in consumption value ($ Million), 2018-2029

Global Acute Myeloid Leukemia (AML) Biomarker Testing market shares of main players, in revenue ($ Million), 2018-2023

The Primary Objectives in This Report Are:

To determine the size of the total market opportunity of global and key countries

To assess the growth potential for Acute Myeloid Leukemia (AML) Biomarker Testing

To forecast future growth in each product and end-use market

To assess competitive factors affecting the marketplace

This report profiles key players in the global Acute Myeloid Leukemia (AML) Biomarker Testing market based on the following parameters - company overview, production, value, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Abbott Laboratories, Novartis AG, Thermo Fisher Scientific, Cancer Genetics Inc. and Sysmex Corporation, etc.

This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, COVID-19 and Russia-Ukraine War Influence.

Market segmentation

Acute Myeloid Leukemia (AML) Biomarker Testing market is split by Type and by Application. For the period 2018-2029, the growth among segments provide accurate calculations and forecasts for consumption value by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.

Market segment by Type

Genetic Acute Myeloid Leukemia (AML) Biomarker

Epigenetic Acute Myeloid Leukemia (AML) Biomarker

Proteomic Acute Myeloid Leukemia (AML) Biomarker

Market segment by Application

Hospitals

Cancer diagnostic Centers

Research Institutes

Others

Market segment by players, this report covers

Abbott Laboratories

Novartis AG

Thermo Fisher Scientific

Cancer Genetics Inc.

Sysmex Corporation

Epigenomics AG

BioMerieux SA

Skyline DX B.V.

Market segment by regions, regional analysis covers

North America (United States, Canada, and Mexico)

Europe (Germany, France, UK, Russia, Italy, and Rest of Europe)

Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Australia and Rest of Asia-Pacific)

South America (Brazil, Argentina and Rest of South America)

Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)

The content of the study subjects, includes a total of 13 chapters:

Chapter 1, to describe Acute Myeloid Leukemia (AML) Biomarker Testing product scope, market overview, market estimation caveats and base year.

Chapter 2, to profile the top players of Acute Myeloid Leukemia (AML) Biomarker Testing, with revenue, gross margin and global market share of Acute Myeloid Leukemia (AML) Biomarker Testing from 2018 to 2023.

Chapter 3, the Acute Myeloid Leukemia (AML) Biomarker Testing competitive situation, revenue and global market share of top players are analyzed emphatically by landscape contrast.

Chapter 4 and 5, to segment the market size by Type and application, with consumption value and growth rate by Type, application, from 2018 to 2029.

Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2018 to 2023.and Acute Myeloid Leukemia (AML) Biomarker Testing market forecast, by regions, type and application, with consumption value, from 2024 to 2029.

Chapter 11, market dynamics, drivers, restraints, trends, Porters Five Forces analysis, and Influence of COVID-19 and Russia-Ukraine War

Chapter 12, the key raw materials and key suppliers, and industry chain of Acute Myeloid Leukemia (AML) Biomarker Testing.

Chapter 13, to describe Acute Myeloid Leukemia (AML) Biomarker Testing research findings and conclusion.

Frequently Asked Questions

The base year for the study has been considered 2019, historic year 2014 and 2018, the forecast period considered is from 2020 to 2027. The regions analyzed for the market include North America, Europe, South America, Asia Pacific, and Middle East and Africa. These regions are further analyzed at the country-level. The study also includes attractiveness analysis of type, application and regions which are benchmarked based on their market size, growth rate and attractiveness in terms of present and future opportunity for understanding the future growth of the market.

Market is segmented on the basis:

  • By Type
  • By Application
  • By Region
  • By Country
  • By Manufacturer

The report offers in-depth analysis of driving factors, opportunities, restraints, and challenges for gaining the key insight of the market. The report emphasizes on all the key trends that play a vital role in the enlargement of the market from 2019 to 2026.

The report provides company profile of the key players operating in the market and a comparative analysis based on their business overviews industry offering, segment market share, regional presence, business strategies, innovations, mergers & acquisitions, recent developments, joint venture, collaborations, partnerships, SWOT analysis, and key financial information.

1 Market Overview

1.1 Product Overview and Scope of Acute Myeloid Leukemia (AML) Biomarker Testing

1.2 Market Estimation Caveats and Base Year

1.3 Classification of Acute Myeloid Leukemia (AML) Biomarker Testing by Type

1.3.1 Overview: Global Acute Myeloid Leukemia (AML) Biomarker Testing Market Size by Type: 2018 Versus 2022 Versus 2029

1.3.2 Global Acute Myeloid Leukemia (AML) Biomarker Testing Consumption Value Market Share by Type in 2022

1.3.3 Genetic Acute Myeloid Leukemia (AML) Biomarker

1.3.4 Epigenetic Acute Myeloid Leukemia (AML) Biomarker

1.3.5 Proteomic Acute Myeloid Leukemia (AML) Biomarker

1.4 Global Acute Myeloid Leukemia (AML) Biomarker Testing Market by Application

1.4.1 Overview: Global Acute Myeloid Leukemia (AML) Biomarker Testing Market Size by Application: 2018 Versus 2022 Versus 2029

1.4.2 Hospitals

1.4.3 Cancer diagnostic Centers

1.4.4 Research Institutes

1.4.5 Others

1.5 Global Acute Myeloid Leukemia (AML) Biomarker Testing Market Size & Forecast

1.6 Global Acute Myeloid Leukemia (AML) Biomarker Testing Market Size and Forecast by Region

1.6.1 Global Acute Myeloid Leukemia (AML) Biomarker Testing Market Size by Region: 2018 VS 2022 VS 2029

1.6.2 Global Acute Myeloid Leukemia (AML) Biomarker Testing Market Size by Region, (2018-2029)

1.6.3 North America Acute Myeloid Leukemia (AML) Biomarker Testing Market Size and Prospect (2018-2029)

1.6.4 Europe Acute Myeloid Leukemia (AML) Biomarker Testing Market Size and Prospect (2018-2029)

1.6.5 Asia-Pacific Acute Myeloid Leukemia (AML) Biomarker Testing Market Size and Prospect (2018-2029)

1.6.6 South America Acute Myeloid Leukemia (AML) Biomarker Testing Market Size and Prospect (2018-2029)

1.6.7 Middle East and Africa Acute Myeloid Leukemia (AML) Biomarker Testing Market Size and Prospect (2018-2029)

2 Company Profiles

2.1 Abbott Laboratories

2.1.1 Abbott Laboratories Details

2.1.2 Abbott Laboratories Major Business

2.1.3 Abbott Laboratories Acute Myeloid Leukemia (AML) Biomarker Testing Product and Solutions

2.1.4 Abbott Laboratories Acute Myeloid Leukemia (AML) Biomarker Testing Revenue, Gross Margin and Market Share (2018-2023)

2.1.5 Abbott Laboratories Recent Developments and Future Plans

2.2 Novartis AG

2.2.1 Novartis AG Details

2.2.2 Novartis AG Major Business

2.2.3 Novartis AG Acute Myeloid Leukemia (AML) Biomarker Testing Product and Solutions

2.2.4 Novartis AG Acute Myeloid Leukemia (AML) Biomarker Testing Revenue, Gross Margin and Market Share (2018-2023)

2.2.5 Novartis AG Recent Developments and Future Plans

2.3 Thermo Fisher Scientific

2.3.1 Thermo Fisher Scientific Details

2.3.2 Thermo Fisher Scientific Major Business

2.3.3 Thermo Fisher Scientific Acute Myeloid Leukemia (AML) Biomarker Testing Product and Solutions

2.3.4 Thermo Fisher Scientific Acute Myeloid Leukemia (AML) Biomarker Testing Revenue, Gross Margin and Market Share (2018-2023)

2.3.5 Thermo Fisher Scientific Recent Developments and Future Plans

2.4 Cancer Genetics Inc.

2.4.1 Cancer Genetics Inc. Details

2.4.2 Cancer Genetics Inc. Major Business

2.4.3 Cancer Genetics Inc. Acute Myeloid Leukemia (AML) Biomarker Testing Product and Solutions

2.4.4 Cancer Genetics Inc. Acute Myeloid Leukemia (AML) Biomarker Testing Revenue, Gross Margin and Market Share (2018-2023)

2.4.5 Cancer Genetics Inc. Recent Developments and Future Plans

2.5 Sysmex Corporation

2.5.1 Sysmex Corporation Details

2.5.2 Sysmex Corporation Major Business

2.5.3 Sysmex Corporation Acute Myeloid Leukemia (AML) Biomarker Testing Product and Solutions

2.5.4 Sysmex Corporation Acute Myeloid Leukemia (AML) Biomarker Testing Revenue, Gross Margin and Market Share (2018-2023)

2.5.5 Sysmex Corporation Recent Developments and Future Plans

2.6 Epigenomics AG

2.6.1 Epigenomics AG Details

2.6.2 Epigenomics AG Major Business

2.6.3 Epigenomics AG Acute Myeloid Leukemia (AML) Biomarker Testing Product and Solutions

2.6.4 Epigenomics AG Acute Myeloid Leukemia (AML) Biomarker Testing Revenue, Gross Margin and Market Share (2018-2023)

2.6.5 Epigenomics AG Recent Developments and Future Plans

2.7 BioMerieux SA

2.7.1 BioMerieux SA Details

2.7.2 BioMerieux SA Major Business

2.7.3 BioMerieux SA Acute Myeloid Leukemia (AML) Biomarker Testing Product and Solutions

2.7.4 BioMerieux SA Acute Myeloid Leukemia (AML) Biomarker Testing Revenue, Gross Margin and Market Share (2018-2023)

2.7.5 BioMerieux SA Recent Developments and Future Plans

2.8 Skyline DX B.V.

2.8.1 Skyline DX B.V. Details

2.8.2 Skyline DX B.V. Major Business

2.8.3 Skyline DX B.V. Acute Myeloid Leukemia (AML) Biomarker Testing Product and Solutions

2.8.4 Skyline DX B.V. Acute Myeloid Leukemia (AML) Biomarker Testing Revenue, Gross Margin and Market Share (2018-2023)

2.8.5 Skyline DX B.V. Recent Developments and Future Plans

3 Market Competition, by Players

3.1 Global Acute Myeloid Leukemia (AML) Biomarker Testing Revenue and Share by Players (2018-2023)

3.2 Market Share Analysis (2022)

3.2.1 Market Share of Acute Myeloid Leukemia (AML) Biomarker Testing by Company Revenue

3.2.2 Top 3 Acute Myeloid Leukemia (AML) Biomarker Testing Players Market Share in 2022

3.2.3 Top 6 Acute Myeloid Leukemia (AML) Biomarker Testing Players Market Share in 2022

3.3 Acute Myeloid Leukemia (AML) Biomarker Testing Market: Overall Company Footprint Analysis

3.3.1 Acute Myeloid Leukemia (AML) Biomarker Testing Market: Region Footprint

3.3.2 Acute Myeloid Leukemia (AML) Biomarker Testing Market: Company Product Type Footprint

3.3.3 Acute Myeloid Leukemia (AML) Biomarker Testing Market: Company Product Application Footprint

3.4 New Market Entrants and Barriers to Market Entry

3.5 Mergers, Acquisition, Agreements, and Collaborations

4 Market Size Segment by Type

4.1 Global Acute Myeloid Leukemia (AML) Biomarker Testing Consumption Value and Market Share by Type (2018-2023)

4.2 Global Acute Myeloid Leukemia (AML) Biomarker Testing Market Forecast by Type (2024-2029)

5 Market Size Segment by Application

5.1 Global Acute Myeloid Leukemia (AML) Biomarker Testing Consumption Value Market Share by Application (2018-2023)

5.2 Global Acute Myeloid Leukemia (AML) Biomarker Testing Market Forecast by Application (2024-2029)

6 North America

6.1 North America Acute Myeloid Leukemia (AML) Biomarker Testing Consumption Value by Type (2018-2029)

6.2 North America Acute Myeloid Leukemia (AML) Biomarker Testing Consumption Value by Application (2018-2029)

6.3 North America Acute Myeloid Leukemia (AML) Biomarker Testing Market Size by Country

6.3.1 North America Acute Myeloid Leukemia (AML) Biomarker Testing Consumption Value by Country (2018-2029)

6.3.2 United States Acute Myeloid Leukemia (AML) Biomarker Testing Market Size and Forecast (2018-2029)

6.3.3 Canada Acute Myeloid Leukemia (AML) Biomarker Testing Market Size and Forecast (2018-2029)

6.3.4 Mexico Acute Myeloid Leukemia (AML) Biomarker Testing Market Size and Forecast (2018-2029)

7 Europe

7.1 Europe Acute Myeloid Leukemia (AML) Biomarker Testing Consumption Value by Type (2018-2029)

7.2 Europe Acute Myeloid Leukemia (AML) Biomarker Testing Consumption Value by Application (2018-2029)

7.3 Europe Acute Myeloid Leukemia (AML) Biomarker Testing Market Size by Country

7.3.1 Europe Acute Myeloid Leukemia (AML) Biomarker Testing Consumption Value by Country (2018-2029)

7.3.2 Germany Acute Myeloid Leukemia (AML) Biomarker Testing Market Size and Forecast (2018-2029)

7.3.3 France Acute Myeloid Leukemia (AML) Biomarker Testing Market Size and Forecast (2018-2029)

7.3.4 United Kingdom Acute Myeloid Leukemia (AML) Biomarker Testing Market Size and Forecast (2018-2029)

7.3.5 Russia Acute Myeloid Leukemia (AML) Biomarker Testing Market Size and Forecast (2018-2029)

7.3.6 Italy Acute Myeloid Leukemia (AML) Biomarker Testing Market Size and Forecast (2018-2029)

8 Asia-Pacific

8.1 Asia-Pacific Acute Myeloid Leukemia (AML) Biomarker Testing Consumption Value by Type (2018-2029)

8.2 Asia-Pacific Acute Myeloid Leukemia (AML) Biomarker Testing Consumption Value by Application (2018-2029)

8.3 Asia-Pacific Acute Myeloid Leukemia (AML) Biomarker Testing Market Size by Region

8.3.1 Asia-Pacific Acute Myeloid Leukemia (AML) Biomarker Testing Consumption Value by Region (2018-2029)

8.3.2 China Acute Myeloid Leukemia (AML) Biomarker Testing Market Size and Forecast (2018-2029)

8.3.3 Japan Acute Myeloid Leukemia (AML) Biomarker Testing Market Size and Forecast (2018-2029)

8.3.4 South Korea Acute Myeloid Leukemia (AML) Biomarker Testing Market Size and Forecast (2018-2029)

8.3.5 India Acute Myeloid Leukemia (AML) Biomarker Testing Market Size and Forecast (2018-2029)

8.3.6 Southeast Asia Acute Myeloid Leukemia (AML) Biomarker Testing Market Size and Forecast (2018-2029)

8.3.7 Australia Acute Myeloid Leukemia (AML) Biomarker Testing Market Size and Forecast (2018-2029)

9 South America

9.1 South America Acute Myeloid Leukemia (AML) Biomarker Testing Consumption Value by Type (2018-2029)

9.2 South America Acute Myeloid Leukemia (AML) Biomarker Testing Consumption Value by Application (2018-2029)

9.3 South America Acute Myeloid Leukemia (AML) Biomarker Testing Market Size by Country

9.3.1 South America Acute Myeloid Leukemia (AML) Biomarker Testing Consumption Value by Country (2018-2029)

9.3.2 Brazil Acute Myeloid Leukemia (AML) Biomarker Testing Market Size and Forecast (2018-2029)

9.3.3 Argentina Acute Myeloid Leukemia (AML) Biomarker Testing Market Size and Forecast (2018-2029)

10 Middle East & Africa

10.1 Middle East & Africa Acute Myeloid Leukemia (AML) Biomarker Testing Consumption Value by Type (2018-2029)

10.2 Middle East & Africa Acute Myeloid Leukemia (AML) Biomarker Testing Consumption Value by Application (2018-2029)

10.3 Middle East & Africa Acute Myeloid Leukemia (AML) Biomarker Testing Market Size by Country

10.3.1 Middle East & Africa Acute Myeloid Leukemia (AML) Biomarker Testing Consumption Value by Country (2018-2029)

10.3.2 Turkey Acute Myeloid Leukemia (AML) Biomarker Testing Market Size and Forecast (2018-2029)

10.3.3 Saudi Arabia Acute Myeloid Leukemia (AML) Biomarker Testing Market Size and Forecast (2018-2029)

10.3.4 UAE Acute Myeloid Leukemia (AML) Biomarker Testing Market Size and Forecast (2018-2029)

11 Market Dynamics

11.1 Acute Myeloid Leukemia (AML) Biomarker Testing Market Drivers

11.2 Acute Myeloid Leukemia (AML) Biomarker Testing Market Restraints

11.3 Acute Myeloid Leukemia (AML) Biomarker Testing Trends Analysis

11.4 Porters Five Forces Analysis

11.4.1 Threat of New Entrants

11.4.2 Bargaining Power of Suppliers

11.4.3 Bargaining Power of Buyers

11.4.4 Threat of Substitutes

11.4.5 Competitive Rivalry

11.5 Influence of COVID-19 and Russia-Ukraine War

11.5.1 Influence of COVID-19

11.5.2 Influence of Russia-Ukraine War

12 Industry Chain Analysis

12.1 Acute Myeloid Leukemia (AML) Biomarker Testing Industry Chain

12.2 Acute Myeloid Leukemia (AML) Biomarker Testing Upstream Analysis

12.3 Acute Myeloid Leukemia (AML) Biomarker Testing Midstream Analysis

12.4 Acute Myeloid Leukemia (AML) Biomarker Testing Downstream Analysis

13 Research Findings and Conclusion

14 Appendix

14.1 Methodology

14.2 Research Process and Data Source

14.3 Disclaimer

List of Tables

Table 1. Global Acute Myeloid Leukemia (AML) Biomarker Testing Consumption Value by Type, (USD Million), 2018 & 2022 & 2029

Table 2. Global Acute Myeloid Leukemia (AML) Biomarker Testing Consumption Value by Application, (USD Million), 2018 & 2022 & 2029

Table 3. Global Acute Myeloid Leukemia (AML) Biomarker Testing Consumption Value by Region (2018-2023) & (USD Million)

Table 4. Global Acute Myeloid Leukemia (AML) Biomarker Testing Consumption Value by Region (2024-2029) & (USD Million)

Table 5. Abbott Laboratories Company Information, Head Office, and Major Competitors

Table 6. Abbott Laboratories Major Business

Table 7. Abbott Laboratories Acute Myeloid Leukemia (AML) Biomarker Testing Product and Solutions

Table 8. Abbott Laboratories Acute Myeloid Leukemia (AML) Biomarker Testing Revenue (USD Million), Gross Margin and Market Share (2018-2023)

Table 9. Abbott Laboratories Recent Developments and Future Plans

Table 10. Novartis AG Company Information, Head Office, and Major Competitors

Table 11. Novartis AG Major Business

Table 12. Novartis AG Acute Myeloid Leukemia (AML) Biomarker Testing Product and Solutions

Table 13. Novartis AG Acute Myeloid Leukemia (AML) Biomarker Testing Revenue (USD Million), Gross Margin and Market Share (2018-2023)

Table 14. Novartis AG Recent Developments and Future Plans

Table 15. Thermo Fisher Scientific Company Information, Head Office, and Major Competitors

Table 16. Thermo Fisher Scientific Major Business

Table 17. Thermo Fisher Scientific Acute Myeloid Leukemia (AML) Biomarker Testing Product and Solutions

Table 18. Thermo Fisher Scientific Acute Myeloid Leukemia (AML) Biomarker Testing Revenue (USD Million), Gross Margin and Market Share (2018-2023)

Table 19. Thermo Fisher Scientific Recent Developments and Future Plans

Table 20. Cancer Genetics Inc. Company Information, Head Office, and Major Competitors

Table 21. Cancer Genetics Inc. Major Business

Table 22. Cancer Genetics Inc. Acute Myeloid Leukemia (AML) Biomarker Testing Product and Solutions

Table 23. Cancer Genetics Inc. Acute Myeloid Leukemia (AML) Biomarker Testing Revenue (USD Million), Gross Margin and Market Share (2018-2023)

Table 24. Cancer Genetics Inc. Recent Developments and Future Plans

Table 25. Sysmex Corporation Company Information, Head Office, and Major Competitors

Table 26. Sysmex Corporation Major Business

Table 27. Sysmex Corporation Acute Myeloid Leukemia (AML) Biomarker Testing Product and Solutions

Table 28. Sysmex Corporation Acute Myeloid Leukemia (AML) Biomarker Testing Revenue (USD Million), Gross Margin and Market Share (2018-2023)

Table 29. Sysmex Corporation Recent Developments and Future Plans

Table 30. Epigenomics AG Company Information, Head Office, and Major Competitors

Table 31. Epigenomics AG Major Business

Table 32. Epigenomics AG Acute Myeloid Leukemia (AML) Biomarker Testing Product and Solutions

Table 33. Epigenomics AG Acute Myeloid Leukemia (AML) Biomarker Testing Revenue (USD Million), Gross Margin and Market Share (2018-2023)

Table 34. Epigenomics AG Recent Developments and Future Plans

Table 35. BioMerieux SA Company Information, Head Office, and Major Competitors

Table 36. BioMerieux SA Major Business

Table 37. BioMerieux SA Acute Myeloid Leukemia (AML) Biomarker Testing Product and Solutions

Table 38. BioMerieux SA Acute Myeloid Leukemia (AML) Biomarker Testing Revenue (USD Million), Gross Margin and Market Share (2018-2023)

Table 39. BioMerieux SA Recent Developments and Future Plans

Table 40. Skyline DX B.V. Company Information, Head Office, and Major Competitors

Table 41. Skyline DX B.V. Major Business

Table 42. Skyline DX B.V. Acute Myeloid Leukemia (AML) Biomarker Testing Product and Solutions

Table 43. Skyline DX B.V. Acute Myeloid Leukemia (AML) Biomarker Testing Revenue (USD Million), Gross Margin and Market Share (2018-2023)

Table 44. Skyline DX B.V. Recent Developments and Future Plans

Table 45. Global Acute Myeloid Leukemia (AML) Biomarker Testing Revenue (USD Million) by Players (2018-2023)

Table 46. Global Acute Myeloid Leukemia (AML) Biomarker Testing Revenue Share by Players (2018-2023)

Table 47. Breakdown of Acute Myeloid Leukemia (AML) Biomarker Testing by Company Type (Tier 1, Tier 2, and Tier 3)

Table 48. Market Position of Players in Acute Myeloid Leukemia (AML) Biomarker Testing, (Tier 1, Tier 2, and Tier 3), Based on Revenue in 2022

Table 49. Head Office of Key Acute Myeloid Leukemia (AML) Biomarker Testing Players

Table 50. Acute Myeloid Leukemia (AML) Biomarker Testing Market: Company Product Type Footprint

Table 51. Acute Myeloid Leukemia (AML) Biomarker Testing Market: Company Product Application Footprint

Table 52. Acute Myeloid Leukemia (AML) Biomarker Testing New Market Entrants and Barriers to Market Entry

Table 53. Acute Myeloid Leukemia (AML) Biomarker Testing Mergers, Acquisition, Agreements, and Collaborations

Table 54. Global Acute Myeloid Leukemia (AML) Biomarker Testing Consumption Value (USD Million) by Type (2018-2023)

Table 55. Global Acute Myeloid Leukemia (AML) Biomarker Testing Consumption Value Share by Type (2018-2023)

Table 56. Global Acute Myeloid Leukemia (AML) Biomarker Testing Consumption Value Forecast by Type (2024-2029)

Table 57. Global Acute Myeloid Leukemia (AML) Biomarker Testing Consumption Value by Application (2018-2023)

Table 58. Global Acute Myeloid Leukemia (AML) Biomarker Testing Consumption Value Forecast by Application (2024-2029)

Table 59. North America Acute Myeloid Leukemia (AML) Biomarker Testing Consumption Value by Type (2018-2023) & (USD Million)

Table 60. North America Acute Myeloid Leukemia (AML) Biomarker Testing Consumption Value by Type (2024-2029) & (USD Million)

Table 61. North America Acute Myeloid Leukemia (AML) Biomarker Testing Consumption Value by Application (2018-2023) & (USD Million)

Table 62. North America Acute Myeloid Leukemia (AML) Biomarker Testing Consumption Value by Application (2024-2029) & (USD Million)

Table 63. North America Acute Myeloid Leukemia (AML) Biomarker Testing Consumption Value by Country (2018-2023) & (USD Million)

Table 64. North America Acute Myeloid Leukemia (AML) Biomarker Testing Consumption Value by Country (2024-2029) & (USD Million)

Table 65. Europe Acute Myeloid Leukemia (AML) Biomarker Testing Consumption Value by Type (2018-2023) & (USD Million)

Table 66. Europe Acute Myeloid Leukemia (AML) Biomarker Testing Consumption Value by Type (2024-2029) & (USD Million)

Table 67. Europe Acute Myeloid Leukemia (AML) Biomarker Testing Consumption Value by Application (2018-2023) & (USD Million)

Table 68. Europe Acute Myeloid Leukemia (AML) Biomarker Testing Consumption Value by Application (2024-2029) & (USD Million)

Table 69. Europe Acute Myeloid Leukemia (AML) Biomarker Testing Consumption Value by Country (2018-2023) & (USD Million)

Table 70. Europe Acute Myeloid Leukemia (AML) Biomarker Testing Consumption Value by Country (2024-2029) & (USD Million)

Table 71. Asia-Pacific Acute Myeloid Leukemia (AML) Biomarker Testing Consumption Value by Type (2018-2023) & (USD Million)

Table 72. Asia-Pacific Acute Myeloid Leukemia (AML) Biomarker Testing Consumption Value by Type (2024-2029) & (USD Million)

Table 73. Asia-Pacific Acute Myeloid Leukemia (AML) Biomarker Testing Consumption Value by Application (2018-2023) & (USD Million)

Table 74. Asia-Pacific Acute Myeloid Leukemia (AML) Biomarker Testing Consumption Value by Application (2024-2029) & (USD Million)

Table 75. Asia-Pacific Acute Myeloid Leukemia (AML) Biomarker Testing Consumption Value by Region (2018-2023) & (USD Million)

Table 76. Asia-Pacific Acute Myeloid Leukemia (AML) Biomarker Testing Consumption Value by Region (2024-2029) & (USD Million)

Table 77. South America Acute Myeloid Leukemia (AML) Biomarker Testing Consumption Value by Type (2018-2023) & (USD Million)

Table 78. South America Acute Myeloid Leukemia (AML) Biomarker Testing Consumption Value by Type (2024-2029) & (USD Million)

Table 79. South America Acute Myeloid Leukemia (AML) Biomarker Testing Consumption Value by Application (2018-2023) & (USD Million)

Table 80. South America Acute Myeloid Leukemia (AML) Biomarker Testing Consumption Value by Application (2024-2029) & (USD Million)

Table 81. South America Acute Myeloid Leukemia (AML) Biomarker Testing Consumption Value by Country (2018-2023) & (USD Million)

Table 82. South America Acute Myeloid Leukemia (AML) Biomarker Testing Consumption Value by Country (2024-2029) & (USD Million)

Table 83. Middle East & Africa Acute Myeloid Leukemia (AML) Biomarker Testing Consumption Value by Type (2018-2023) & (USD Million)

Table 84. Middle East & Africa Acute Myeloid Leukemia (AML) Biomarker Testing Consumption Value by Type (2024-2029) & (USD Million)

Table 85. Middle East & Africa Acute Myeloid Leukemia (AML) Biomarker Testing Consumption Value by Application (2018-2023) & (USD Million)

Table 86. Middle East & Africa Acute Myeloid Leukemia (AML) Biomarker Testing Consumption Value by Application (2024-2029) & (USD Million)

Table 87. Middle East & Africa Acute Myeloid Leukemia (AML) Biomarker Testing Consumption Value by Country (2018-2023) & (USD Million)

Table 88. Middle East & Africa Acute Myeloid Leukemia (AML) Biomarker Testing Consumption Value by Country (2024-2029) & (USD Million)

Table 89. Acute Myeloid Leukemia (AML) Biomarker Testing Raw Material

Table 90. Key Suppliers of Acute Myeloid Leukemia (AML) Biomarker Testing Raw Materials

List of Figures

Figure 1. Acute Myeloid Leukemia (AML) Biomarker Testing Picture

Figure 2. Global Acute Myeloid Leukemia (AML) Biomarker Testing Consumption Value by Type, (USD Million), 2018 & 2022 & 2029

Figure 3. Global Acute Myeloid Leukemia (AML) Biomarker Testing Consumption Value Market Share by Type in 2022

Figure 4. Genetic Acute Myeloid Leukemia (AML) Biomarker

Figure 5. Epigenetic Acute Myeloid Leukemia (AML) Biomarker

Figure 6. Proteomic Acute Myeloid Leukemia (AML) Biomarker

Figure 7. Global Acute Myeloid Leukemia (AML) Biomarker Testing Consumption Value by Type, (USD Million), 2018 & 2022 & 2029

Figure 8. Acute Myeloid Leukemia (AML) Biomarker Testing Consumption Value Market Share by Application in 2022

Figure 9. Hospitals Picture

Figure 10. Cancer diagnostic Centers Picture

Figure 11. Research Institutes Picture

Figure 12. Others Picture

Figure 13. Global Acute Myeloid Leukemia (AML) Biomarker Testing Consumption Value, (USD Million): 2018 & 2022 & 2029

Figure 14. Global Acute Myeloid Leukemia (AML) Biomarker Testing Consumption Value and Forecast (2018-2029) & (USD Million)

Figure 15. Global Market Acute Myeloid Leukemia (AML) Biomarker Testing Consumption Value (USD Million) Comparison by Region (2018 & 2022 & 2029)

Figure 16. Global Acute Myeloid Leukemia (AML) Biomarker Testing Consumption Value Market Share by Region (2018-2029)

Figure 17. Global Acute Myeloid Leukemia (AML) Biomarker Testing Consumption Value Market Share by Region in 2022

Figure 18. North America Acute Myeloid Leukemia (AML) Biomarker Testing Consumption Value (2018-2029) & (USD Million)

Figure 19. Europe Acute Myeloid Leukemia (AML) Biomarker Testing Consumption Value (2018-2029) & (USD Million)

Figure 20. Asia-Pacific Acute Myeloid Leukemia (AML) Biomarker Testing Consumption Value (2018-2029) & (USD Million)

Figure 21. South America Acute Myeloid Leukemia (AML) Biomarker Testing Consumption Value (2018-2029) & (USD Million)

Figure 22. Middle East and Africa Acute Myeloid Leukemia (AML) Biomarker Testing Consumption Value (2018-2029) & (USD Million)

Figure 23. Global Acute Myeloid Leukemia (AML) Biomarker Testing Revenue Share by Players in 2022

Figure 24. Acute Myeloid Leukemia (AML) Biomarker Testing Market Share by Company Type (Tier 1, Tier 2 and Tier 3) in 2022

Figure 25. Global Top 3 Players Acute Myeloid Leukemia (AML) Biomarker Testing Market Share in 2022

Figure 26. Global Top 6 Players Acute Myeloid Leukemia (AML) Biomarker Testing Market Share in 2022

Figure 27. Global Acute Myeloid Leukemia (AML) Biomarker Testing Consumption Value Share by Type (2018-2023)

Figure 28. Global Acute Myeloid Leukemia (AML) Biomarker Testing Market Share Forecast by Type (2024-2029)

Figure 29. Global Acute Myeloid Leukemia (AML) Biomarker Testing Consumption Value Share by Application (2018-2023)

Figure 30. Global Acute Myeloid Leukemia (AML) Biomarker Testing Market Share Forecast by Application (2024-2029)

Figure 31. North America Acute Myeloid Leukemia (AML) Biomarker Testing Consumption Value Market Share by Type (2018-2029)

Figure 32. North America Acute Myeloid Leukemia (AML) Biomarker Testing Consumption Value Market Share by Application (2018-2029)

Figure 33. North America Acute Myeloid Leukemia (AML) Biomarker Testing Consumption Value Market Share by Country (2018-2029)

Figure 34. United States Acute Myeloid Leukemia (AML) Biomarker Testing Consumption Value (2018-2029) & (USD Million)

Figure 35. Canada Acute Myeloid Leukemia (AML) Biomarker Testing Consumption Value (2018-2029) & (USD Million)

Figure 36. Mexico Acute Myeloid Leukemia (AML) Biomarker Testing Consumption Value (2018-2029) & (USD Million)

Figure 37. Europe Acute Myeloid Leukemia (AML) Biomarker Testing Consumption Value Market Share by Type (2018-2029)

Figure 38. Europe Acute Myeloid Leukemia (AML) Biomarker Testing Consumption Value Market Share by Application (2018-2029)

Figure 39. Europe Acute Myeloid Leukemia (AML) Biomarker Testing Consumption Value Market Share by Country (2018-2029)

Figure 40. Germany Acute Myeloid Leukemia (AML) Biomarker Testing Consumption Value (2018-2029) & (USD Million)

Figure 41. France Acute Myeloid Leukemia (AML) Biomarker Testing Consumption Value (2018-2029) & (USD Million)

Figure 42. United Kingdom Acute Myeloid Leukemia (AML) Biomarker Testing Consumption Value (2018-2029) & (USD Million)

Figure 43. Russia Acute Myeloid Leukemia (AML) Biomarker Testing Consumption Value (2018-2029) & (USD Million)

Figure 44. Italy Acute Myeloid Leukemia (AML) Biomarker Testing Consumption Value (2018-2029) & (USD Million)

Figure 45. Asia-Pacific Acute Myeloid Leukemia (AML) Biomarker Testing Consumption Value Market Share by Type (2018-2029)

Figure 46. Asia-Pacific Acute Myeloid Leukemia (AML) Biomarker Testing Consumption Value Market Share by Application (2018-2029)

Figure 47. Asia-Pacific Acute Myeloid Leukemia (AML) Biomarker Testing Consumption Value Market Share by Region (2018-2029)

Figure 48. China Acute Myeloid Leukemia (AML) Biomarker Testing Consumption Value (2018-2029) & (USD Million)

Figure 49. Japan Acute Myeloid Leukemia (AML) Biomarker Testing Consumption Value (2018-2029) & (USD Million)

Figure 50. South Korea Acute Myeloid Leukemia (AML) Biomarker Testing Consumption Value (2018-2029) & (USD Million)

Figure 51. India Acute Myeloid Leukemia (AML) Biomarker Testing Consumption Value (2018-2029) & (USD Million)

Figure 52. Southeast Asia Acute Myeloid Leukemia (AML) Biomarker Testing Consumption Value (2018-2029) & (USD Million)

Figure 53. Australia Acute Myeloid Leukemia (AML) Biomarker Testing Consumption Value (2018-2029) & (USD Million)

Figure 54. South America Acute Myeloid Leukemia (AML) Biomarker Testing Consumption Value Market Share by Type (2018-2029)

Figure 55. South America Acute Myeloid Leukemia (AML) Biomarker Testing Consumption Value Market Share by Application (2018-2029)

Figure 56. South America Acute Myeloid Leukemia (AML) Biomarker Testing Consumption Value Market Share by Country (2018-2029)

Figure 57. Brazil Acute Myeloid Leukemia (AML) Biomarker Testing Consumption Value (2018-2029) & (USD Million)

Figure 58. Argentina Acute Myeloid Leukemia (AML) Biomarker Testing Consumption Value (2018-2029) & (USD Million)

Figure 59. Middle East and Africa Acute Myeloid Leukemia (AML) Biomarker Testing Consumption Value Market Share by Type (2018-2029)

Figure 60. Middle East and Africa Acute Myeloid Leukemia (AML) Biomarker Testing Consumption Value Market Share by Application (2018-2029)

Figure 61. Middle East and Africa Acute Myeloid Leukemia (AML) Biomarker Testing Consumption Value Market Share by Country (2018-2029)

Figure 62. Turkey Acute Myeloid Leukemia (AML) Biomarker Testing Consumption Value (2018-2029) & (USD Million)

Figure 63. Saudi Arabia Acute Myeloid Leukemia (AML) Biomarker Testing Consumption Value (2018-2029) & (USD Million)

Figure 64. UAE Acute Myeloid Leukemia (AML) Biomarker Testing Consumption Value (2018-2029) & (USD Million)

Figure 65. Acute Myeloid Leukemia (AML) Biomarker Testing Market Drivers

Figure 66. Acute Myeloid Leukemia (AML) Biomarker Testing Market Restraints

Figure 67. Acute Myeloid Leukemia (AML) Biomarker Testing Market Trends

Figure 68. Porters Five Forces Analysis

Figure 69. Manufacturing Cost Structure Analysis of Acute Myeloid Leukemia (AML) Biomarker Testing in 2022

Figure 70. Manufacturing Process Analysis of Acute Myeloid Leukemia (AML) Biomarker Testing

Figure 71. Acute Myeloid Leukemia (AML) Biomarker Testing Industrial Chain

Figure 72. Methodology

Figure 73. Research Process and Data Source

shopping_cart License Type

Buy Now

email Quick Contact

tag_faces Our Clients

help Need Help?

Please contact directly on our US and India numbers

+1-201-465-4211

Please feel free to write an email to us or to use our electronic ticketing system.

sales@marketsandresearch.biz